As SMN2 is present in all SMA patients it has been extensively studied and serves as a drug target for drugs that specifically correct splicing of exon 7 and thereby increases amounts of functional SMN protein [15]–[17]. Here, SMN2 is linked to proximal spinal muscular atrophy.